Recommendations of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) to address vulnerabilities in the supply chain of radiopharmaceuticals

Recommendations of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) to address vulnerabilities in the supply chain of radiopharmaceuticals

Guidance on the anonymisation of protected personal data and assessment of commercially confidential information during the preparation of RMPs (main body and annexes 4 and 6)

Guidance on the anonymisation of protected personal data and assessment of commercially confidential information during the preparation of RMPs (main body and annexes 4 and 6)

Human medicines European public assessment report (EPAR): Cinqaero, reslizumab, Date of authorisation: 15/08/2016, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Cinqaero, reslizumab, Date of authorisation: 15/08/2016, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Edurant, rilpivirine, Date of authorisation: 28/11/2011, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Edurant, rilpivirine, Date of authorisation: 28/11/2011, Revision: 22, Status: Authorised

Template for the qualified person's (QP) declaration concerning good manufacturing practice compliance of active substance manufacture "The QP declaration template" - Scientific guideline

Template for the qualified person's (QP) declaration concerning good manufacturing practice compliance of active substance manufacture "The QP declaration template" - Scientific guideline

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness